KINDER PHARM Trademark

Trademark Overview

On Thursday, May 1, 2014, a trademark application was filed for KINDER PHARM with the United States Patent and Trademark Office. The USPTO has given the KINDER PHARM trademark a serial number of 86268843. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, November 4, 2022. This trademark is owned by Kinderpharm LLC. The KINDER PHARM trademark is filed in the Advertising, Business and Retail Services category with the following description:

Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval
kinder pharm

General Information

Serial Number86268843
Word MarkKINDER PHARM
Filing DateThursday, May 1, 2014
Status710 - CANCELLED - SECTION 8
Status DateFriday, November 4, 2022
Registration Number4941924
Registration DateTuesday, April 19, 2016
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 14, 2015

Trademark Statements

Description of MarkThe mark consists of the stylized word "KINDER" written in red with a red 5-point star over the "I" and a red downward facing curved line above the word "KINDER" followed by the stylized word "PHARM" written in navy blue with an upward facing navy blue curved line below the word "PHARM".
Pseudo MarkKINDER PHARMACEUTICAL
Indication of Colors claimedThe color(s) red and navy blue is/are claimed as a feature of the mark.
Goods and ServicesBusiness consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval
Translation of Words in MarkThe English translation of "KINDER" in the mark is "CHILDREN".
Disclaimer with Predetermined Text"KINDER PHARM"

Classification Information

International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, November 4, 2022
Primary Code035
First Use Anywhere DateWednesday, January 1, 2014
First Use In Commerce DateWednesday, January 1, 2014

Trademark Owner History

Party NameSYNTERACT,INC.
Party Type31 - New Owner After Registration
Legal Entity Type03 - Corporation
AddressCARLSBAD, CA 92010
Party NameKinderpharm LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressExton, PA 19341
Party NameKinderpharm LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressExton, PA 19341
Party NameKinderpharm LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressExton, PA 19341

Trademark Events

Event DateEvent Description
Wednesday, October 4, 2023ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Friday, November 4, 2022CANCELLED SEC. 8 (6-YR)
Wednesday, May 19, 2021ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Tuesday, September 10, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, September 10, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, February 14, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 14, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, January 16, 2019AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, April 19, 2016REGISTERED-PRINCIPAL REGISTER
Tuesday, March 15, 2016NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Saturday, March 12, 2016ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Saturday, March 12, 2016EXAMINER'S AMENDMENT ENTERED
Saturday, March 12, 2016NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Saturday, March 12, 2016EXAMINERS AMENDMENT E-MAILED
Saturday, March 12, 2016SU-EXAMINER'S AMENDMENT WRITTEN
Friday, March 11, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 11, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 4, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, September 19, 2015NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, September 19, 2015NON-FINAL ACTION E-MAILED
Saturday, September 19, 2015SU - NON-FINAL ACTION - WRITTEN
Friday, September 18, 2015STATEMENT OF USE PROCESSING COMPLETE
Wednesday, September 9, 2015USE AMENDMENT FILED
Thursday, September 17, 2015CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, September 9, 2015TEAS STATEMENT OF USE RECEIVED
Tuesday, June 9, 2015NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 14, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 14, 2015PUBLISHED FOR OPPOSITION
Wednesday, March 25, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, March 6, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, March 3, 2015ASSIGNED TO LIE
Thursday, February 12, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 11, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 10, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 10, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 10, 2015NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, February 10, 2015NON-FINAL ACTION E-MAILED
Tuesday, February 10, 2015NON-FINAL ACTION WRITTEN
Wednesday, January 21, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 20, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 20, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 14, 2014NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, August 14, 2014NON-FINAL ACTION E-MAILED
Thursday, August 14, 2014NON-FINAL ACTION WRITTEN
Thursday, August 14, 2014ASSIGNED TO EXAMINER
Friday, May 16, 2014NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, May 15, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, May 5, 2014NEW APPLICATION ENTERED

Related Keywords

pharm kinder clinical management trials assist companies biotechnology them research approval biopharmaceutical